Abstract
HIV-1 entry is an attractive target for anti-HIV-1 therapy. However, there are no entry inhibitors approved for the clinical treatment of HIV-1 infection. This is likely to be changed in the near future since promising HIV-1 entry inhibitors, such as T20 and some chemokine receptor antagonists, are in the pipeline to join the repertoire of anti-HIV-1 therapeutics. This review will focus on what might be potential targets on the key components of the viral entry machinery, gp120 and gp41. These two molecules are the viral proteins responsible for HIV-1 entry. Binding to CD4 induces a series of structural changes in gp120 and allows it to interact with chemokine receptors. The receptor binding eventually triggers conformational changes in gp41, which result in the formation of a fusion active molecule to attack the cell membrane. The structural and functional motifs that operate this delicate fusion machinery could become the Achilles heel of the virus.
Keywords: hiv-1 envelope glycoproteins, anti-hiv-1 therapy, chemokine receptor antagonists, gp120, gp41
Current Pharmaceutical Design
Title: Potential Drug Targets on the HIV-1 Envelope Glycoproteins, gp120 and gp41
Volume: 9 Issue: 18
Author(s): Li Huang, Linda Zhang and Chin Ho Chen
Affiliation:
Keywords: hiv-1 envelope glycoproteins, anti-hiv-1 therapy, chemokine receptor antagonists, gp120, gp41
Abstract: HIV-1 entry is an attractive target for anti-HIV-1 therapy. However, there are no entry inhibitors approved for the clinical treatment of HIV-1 infection. This is likely to be changed in the near future since promising HIV-1 entry inhibitors, such as T20 and some chemokine receptor antagonists, are in the pipeline to join the repertoire of anti-HIV-1 therapeutics. This review will focus on what might be potential targets on the key components of the viral entry machinery, gp120 and gp41. These two molecules are the viral proteins responsible for HIV-1 entry. Binding to CD4 induces a series of structural changes in gp120 and allows it to interact with chemokine receptors. The receptor binding eventually triggers conformational changes in gp41, which result in the formation of a fusion active molecule to attack the cell membrane. The structural and functional motifs that operate this delicate fusion machinery could become the Achilles heel of the virus.
Export Options
About this article
Cite this article as:
Huang Li, Zhang Linda and Chen Ho Chin, Potential Drug Targets on the HIV-1 Envelope Glycoproteins, gp120 and gp41, Current Pharmaceutical Design 2003; 9 (18) . https://dx.doi.org/10.2174/1381612033454720
DOI https://dx.doi.org/10.2174/1381612033454720 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Immunotherapy in Breast Cancer- Paving New Roads?
Current Molecular Pharmacology Structural and Mechanistic Insights of CRAC Channel as a Drug Target in Autoimmune Disorder
Current Drug Targets Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Synthetic Peptides Derived from the C-Terminal Region of Lys49 Phospholipase A2 Homologues from Viperidae Snake Venoms: Biomimetic Activities and Potential Applications
Current Pharmaceutical Design Antibodies and their Multivalent Constructs for Cancer Therapy
Protein & Peptide Letters Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets The Impact of IKr Blockade on Medicinal Chemistry Programs
Current Topics in Medicinal Chemistry Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy Human- and Virus-Encoded microRNAs as Potential Targets of Antiviral Therapy
Mini-Reviews in Medicinal Chemistry Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus
Current Gene Therapy Molecular Modeling Applied to Anti-Cancer Drug Development
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Cancer Therapy Reviews